halicyclamine a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

halicyclamine A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10479489
CHEMBL ID	461499
SCHEMBL ID	3130992
MeSH ID	M0463033

Synonyms (4)

Synonym
halicyclamine a
CHEMBL461499
SCHEMBL3130992
(4e,6z,14s,19z,21z,29s,30r)-1,16-diazatetracyclo[27.3.1.112,16.014,30]tetratriaconta-4,6,12,19,21-pentaene

Research Excerpts

Effects

Excerpt	Reference	Relevance
"Halicyclamine A has been isolated originally as one of the active constituents inhibiting inosine 5'-monophosphate dehydrogenase (IMPDH)."	( Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent. Arai, M; Baughn, A; Hashizume, H; Ishida, S; Jacobs, WR; Kobayashi, M; Matsumoto, M; Pruksakorn, P; Sobou, M; Vilchéze, C, 2008)	2.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay ID	Title	Year	Journal	Article
AID344029	Bactericidal activity against Mycobacterium bovis BCG assessed as decrease in CFU at 10 ug/ml after 4 weeks	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344026	Antitubercular activity against Mycobacterium fortuitum ATCC 9820 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344012	Antitubercular activity against Mycobacterium smegmatis MC2 155 under hypoxic condition after 96 hrs by MTT method	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344016	Antitubercular activity against Mycobacterium tuberculosis H37Ra under hypoxic condition after 14 days by MTT method	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344014	Antitubercular activity against Mycobacterium bovis BCG under hypoxic condition after 14 days by MTT method	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344030	Bactericidal activity against Mycobacterium tuberculosis H37Rv assessed as decrease in CFU at 20 ug/ml after 11 to 28 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344027	Antitubercular activity against Mycobacterium aurum ATCC 23366 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID1601820	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Marine natural products as potential anti-tubercular agents.
AID344033	Antitubercular activity against guaB2 gene over-expressed Mycobacterium smegmatis MC2 155 ICHO1003	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344024	Antitubercular activity against Mycobacterium intracellular ATCC 35761 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344019	Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 35822 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344021	Antitubercular activity against streptomycin-resistant Mycobacterium tuberculosis H37Rv ATCC 35820 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344020	Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv ATCC 35838 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344011	Antitubercular activity against Mycobacterium smegmatis MC2 155 under aerobic condition after 24 hrs by MTT method	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344023	Antitubercular activity against Mycobacterium avium ATCC 35712 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344013	Antitubercular activity against Mycobacterium bovis BCG under aerobic condition after 7 days by MTT method	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344032	Antitubercular activity against guaB1 gene over-expressed Mycobacterium smegmatis MC2 155 ICHO1002	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344031	Antitubercular activity against Mycobacterium smegmatis MC2 155 ICHO1001 with pMV261 transformant	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344025	Antitubercular activity against Mycobacterium kansasii ATCC 35775 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344017	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 25618 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID1601822	Antimycobacterial activity against Mycobacterium bovis BCG	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Marine natural products as potential anti-tubercular agents.
AID344028	Bactericidal activity against Mycobacterium smegmatis MC2 155 assessed as decrease in CFU at 10 ug/ml after 4 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344018	Antitubercular activity against ethambutol-resistant Mycobacterium tuberculosis H37Rv ATCC 35837 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344294	Antitubercular activity against guaB3 gene over-expressed Mycobacterium smegmatis MC2 155 ICHO1004	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344015	Antitubercular activity against Mycobacterium tuberculosis H37Ra under aerobic condition after 7 days by MTT method	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID1601821	Antimycobacterial activity against Mycobacterium smegmatis	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Marine natural products as potential anti-tubercular agents.
AID344022	Antitubercular activity against Mycobacterium tuberculosis Kurono ATCC 35812 after 14 days	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.63 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.42 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (20.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.59	2	carbohydrazide	antitubercular agent; drug allergen
gliotoxin Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.	3.31	1	dipeptide; organic disulfide; organic heterotetracyclic compound; pyrazinoindole	antifungal agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; immunosuppressive agent; mycotoxin; proteasome inhibitor
puupehenone [no description available]	3.31	1
24-methylenecholesterol 24-methylenecholesterol: RN given refers to (3beta)-isomer; structure. 24-methylenecholesterol : A 3beta-sterol having the structure of cholesterol with a methylene group at C-24.	3.31	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol	mouse metabolite
brevianamide f brevianamide F: isolated from the endophyte from Aspergillus fumigatus associated with Melia azedarach L that could be used to develop a natural eco-friendly herbicide.structure in first source. brevianamide F : A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione bearing an indol-3-ylmethyl substituent at position 3 (the 3S,8aS-diastereomer, obtained by formal cyclocondensation of L-tryptophan and L-proline).	3.31	1	dipeptide; indoles; pyrrolopyrazine	metabolite
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2.05	1
epinephrine ircinal A: from an Indonesian Acanthostrongylophora sponge with activity against infectious, tropical parasitic, and Alzheimer's diseases; structure in first source	3.31	1
caulerpin caulerpin: pigment from green algae, Caulerpa lamourouxii; structure	3.31	1
sclerotiorin sclerotiorin: isolated from monoverticillate Penicillia; RN given for (R-(R,S-(E,E)))-isomer; structure in first source	3.31	1	azaphilone
pseudopteroxazole pseudopteroxazole: structure in first source	3.31	1	tetralins	metabolite
manzamine a manzamine A: RN given refers to (1R-(1R,9Z,13S,13aR,20aR,21aR*)-isomer; RN for cpd without isomeric designation not avail 12/92. manzamine A : An alkaloid of the class of beta-carbolines isolated from Haliclona and Acanthostrongylophora. It exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).	3.31	1	alkaloid; beta-carbolines; isoquinolines	animal metabolite; anti-HSV-1 agent; antimalarial; antineoplastic agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; marine metabolite
1,4-dihydroxy-2-methoxy-7-methylanthraquinone [no description available]	3.31	1
proximicin b proximicin B: antineoplastic agent isolated from Verrucosispora; structure in first source	3.31	1
piperidines Piperidines: A family of hexahydropyridines.	2.96	4
sch 419560 Sch 419560: isolated from Pseudomonas fluorescens; structure in first source	3.31	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.31	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
4-deoxybostrycin 4-deoxybostrycin: crystalline red pigment from culture filtrate of Alternaria eichhorniae with antibacterial & phytotoxic activity; structure given in first source	3.31	1

Condition	Indicated	Relationship Strength	Studies	Trials
Koch's Disease [description not available]	0	3.12	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	0	3.12	1	0

chemdatabank.com